Lunai Bioworks (LNAI) Stock Price, News & Analysis

Company Overview

Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.

Key Stats

• Today's Range: $1.20 to $1.20
• 50-Day Range: N/A
• 52-Week Range: $1.11 to $21.00
• Volume: 4,940 shs
• Average Volume: 232,103 shs
• Market Capitalization: $27.82 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

LNAI Stock Analysis - Frequently Asked Questions

How have LNAI shares performed this year?

Lunai Bioworks' stock was trading at $1.29 on January 1st, 2025. Since then, LNAI stock has decreased by 7.0% and is now trading at $1.20.

How were Lunai Bioworks' earnings last quarter?

Lunai Bioworks Inc. (NASDAQ:LNAI) issued its quarterly earnings results on Monday, September, 29th. The company reported ($76.00) earnings per share (EPS) for the quarter.

When did Lunai Bioworks' stock split?

Lunai Bioworks's stock reverse split before market open on Tuesday, September 30th 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 29th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Lunai Bioworks?

Shares of LNAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 9/29/2025
• Today: 10/20/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LNAI
• CIK: N/A
• Web: N/A
• Phone: (453) 917-9840
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($7.70)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$178.01 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -222.12%
• Return on Assets: -152.88%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.04
• Quick Ratio: 0.04

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.24) per share
• Price / Book: -0.97

Miscellaneous

• Outstanding Shares: 23,180,000
• Free Float: 23,062,000
• Market Cap: $27.82 million
• Optionable: N/A
• Beta: 0.39